In a patient with cirrhosis and acute kidney injury meeting criteria for hepatorenal syndrome, what is the recommended first‑line treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hepatorenal Syndrome: First-Line Treatment

The recommended first-line treatment for hepatorenal syndrome-AKI (HRS-AKI) is the combination of terlipressin plus intravenous albumin, initiated after a 48-hour trial of volume expansion with albumin (1 g/kg/day, maximum 100 g/day) fails to improve kidney function. 1, 2

Initial Management Algorithm

Step 1: Exclude Other Causes and Volume Resuscitate

Before diagnosing HRS-AKI, you must:

  • Withdraw diuretics and beta-blockers immediately 1
  • Rule out infection aggressively - perform diagnostic paracentesis, blood/urine cultures, and chest X-ray 1
  • Discontinue all nephrotoxic agents (NSAIDs, contrast) 1
  • Administer albumin 1 g/kg IV on day 1 (maximum 100 g), then 20-40 g daily for 48 hours 1, 2

Step 2: Diagnose HRS-AKI

If serum creatinine remains ≥2x baseline after 48 hours of albumin, diagnose HRS-AKI and proceed to vasoconstrictor therapy 1. This applies specifically to Stage 2 or greater HRS-AKI; there is currently no recommendation for vasoconstrictor use in Stage 1 AKI 2.

First-Line Pharmacologic Treatment

Terlipressin + Albumin (Preferred)

Terlipressin is the first-line vasoconstrictor 3, though it was only recently FDA-approved in the United States 4.

Dosing regimen:

  • Start: 1 mg IV bolus every 4-6 hours (total 4-6 mg/day) 1
  • Alternative: Continuous IV infusion starting at 2 mg/day (may reduce ischemic side effects) 1
  • Escalation: If creatinine doesn't decrease ≥25% by day 3, increase to 2 mg every 4-6 hours (maximum 8-12 mg/day) 1, 3
  • Duration: Continue until creatinine returns to within 0.3 mg/dL of baseline for 2 consecutive days, or maximum 14 days 1, 3

Albumin dosing with terlipressin:

  • Day 1: 1 g/kg IV
  • Subsequent days: 20-40 g/day 1, 2, 5

FDA contraindications for terlipressin:

  • Serum creatinine ≥5 mg/dL
  • Oxygen saturation <90% 1

Alternative Vasoconstrictors

Norepinephrine (second choice, requires ICU):

  • Start: 0.5 mg/hour continuous IV infusion 1
  • Goal: Increase MAP by ≥10 mmHg and/or urine output >50 mL/hour for ≥4 hours 1
  • Escalation: Increase by 0.5 mg/hour every 4 hours to maximum 3 mg/hour 1
  • Preferred in patients with shock 2

The 2024 AASLD guidance explicitly states norepinephrine can be used as an alternative to terlipressin 2, and the 2022 AGA update confirms it appears equally effective 5.

Midodrine + Octreotide (least effective, avoid if possible):

  • Midodrine: Start 7.5 mg PO, titrate to 12.5 mg three times daily 1, 3
  • Octreotide: Start 100 mcg SC, titrate to 200 mcg three times daily 1, 3
  • This combination is significantly inferior to terlipressin 1, 5 and should largely be abandoned due to lack of efficacy 6

Critical Safety Monitoring

Ischemic Complications

Both terlipressin and norepinephrine carry risk of:

  • Angina/myocardial ischemia
  • Digital/skin ischemia
  • Intestinal ischemia 1

Mitigation strategy: Start at lowest dose and titrate gradually 1

Volume Overload

Monitor closely for pulmonary edema from excessive albumin administration 1. Recent evidence suggests fixed-dose albumin in unselected AKI patients may cause harm via volume overload 6. Use clinical assessment, vital signs, urine output, and when indicated, echocardiography or CVP monitoring 1.

Renal Replacement Therapy

RRT should be reserved for:

  • HRS-AKI patients who are liver transplant candidates or being evaluated for transplant 1, 5
  • Patients with acute tubular necrosis 1
  • RRT should NOT be used as first-line therapy or in non-transplant candidates with HRS-AKI 1, 5

Continuous RRT is preferred over intermittent hemodialysis due to better hemodynamic stability 1, 5.

Liver Transplantation

Liver transplantation is the definitive treatment for HRS-AKI 1, 3, 1, 3. All patients with HRS-AKI should be referred for transplant evaluation immediately 2.

Important consideration: Treatment with vasoconstrictors before transplant improves post-transplant outcomes, with fewer patients requiring RRT and developing chronic kidney disease at 1 year 2, 5. Therefore, do not withhold vasoconstrictor therapy even if it lowers MELD score 5.

Common Pitfalls

  1. Delaying vasoconstrictor therapy: Recent data emphasize that effective treatment requires rapid diagnosis within 24 hours, not waiting the full 48-hour albumin trial if HRS-AKI is clinically obvious 6, 7

  2. Using midodrine/octreotide as first-line: This combination is significantly less effective than terlipressin or norepinephrine 1, 5, 6

  3. Avoiding TIPS: TIPS should NOT be used as specific treatment for HRS-AKI 1

  4. Inappropriate RRT use: Do not initiate RRT in non-transplant candidates with HRS-AKI, as mortality approaches 100% 5

References

4
Research

The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2021

Related Questions

What are the diagnostic criteria and treatment options for Hepatorenal Syndrome (HRS)?
What is the recommended dose of albumin for treating hepatorenal syndrome (HRS) in adult patients with cirrhosis?
What are the recommended albumin, terlipressin, and norepinephrine dosing regimens and infusion durations for treating hepatorenal syndrome?
What is the pathophysiology of hepatorenal syndrome?
What is the recommended intravenous human albumin dose for treating hepatorenal syndrome?
Between pregabalin and gabapentin oral tablets, which is safer, has fewer adverse reactions, and is more effective for neuropathic pain?
In a 67-year-old asymptomatic woman in a monogamous relationship with no history of sexually transmitted infections, a negative HIV test over 20 years ago, no prior hepatitis testing, and no injection drug use, which screening test is most appropriate at this time?
Can a medication with an expiration date of March 2026 be used throughout that month?
What is the recommended treatment for vasospastic (Prinzmetal) angina?
What are the guideline-recommended TSH reference ranges for elderly patients (aged 65 years and older) and how should they guide hypothyroidism management?
How can I increase my high‑density lipoprotein (HDL) cholesterol levels?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question